• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Ophthalmology

Doxycycline may improve vision in nonproliferative diabetic retinopathy

bySwarup Swaminathan, MDandAndrew Bishara
March 7, 2014
in Ophthalmology, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. At 24 months, frequency doubling perimetry (FDP) foveal sensitivity was significantly decreased in the placebo group (-1.9 dB) and increased in the group treated with Doxycycline (+1.8 dB, p=0.02). This difference was consistently observed beginning at 6 months.

2. There were no other significant differences between the placebo and Doxycycline arms among functional and anatomic metrics.

Evidence Rating Level: 2 (Good)

Study Rundown: This study aimed to identify whether the anti-inflammatory component of doxycycline could impede progression of nonproliferative diabetic retinopathy. Thirty patients were divided into placebo and treatment arms, with the latter receiving daily doxycycline for 24 months. While multiple functional and anatomic markers were used as metrics to identify any changes, only frequency doubling perimetry (FDP) foveal sensitivity was significantly elevated among the treatment arm, but decreased among the control group beginning at the 6-month mark and persisting through 24 months (p=0.02-0.04). None of the other markers were significantly different between the groups. This may have been due to the small sample size or short length of study, both which were limitations. It is also possible that given the subtle nature of nonproliferative diabetic retinopathy, these tests were not sufficiently sensitive to detect change. Another limitation is that not all measurements could be completed at 24 months, significantly reducing the statistical power at this time point. Ultimately, this study encourages further investigation into the role of inflammation in diabetic retinopathy.

Click to read the study in JAMA Ophthalmology

Relevant Reading: Inner retinal visual dysfunction is a sensitive marker of non-proliferative diabetic retinopathy

RELATED REPORTS

Faricimab noninferior to aflibercept for treatment of neovascular age-related macular degeneration

Faricimab may improve visual acuity in patients with diabetic macular edema

Open-label placebo effective therapy for children with functional abdominal pain or irritable bowel syndrome

In-Depth [randomized control trial]: In this study, the authors attempted to study whether a daily low-dose of doxycycline can impair the progression of diabetic retinopathy or perhaps improve vision. Patients were randomized to either receive placebo or low-dose doxycycline for 24 months. Multiple functional and anatomic metrics were utilized as outcome measures, including frequency doubling perimetry (FDP), contrast sensitivity, visual acuity, quality of life, retinal thickening, macular thickness, and retinal vessel diameters. FDP is thought to be a sensitive measure of inner retinal function, which is often affected in diabetes and mild diabetic retinopathy. At 12 months, FDP foveal sensitivity was significantly decreased in the placebo (-1.60 dB) and increased in the treatment group (+1.66 dB, p=0.04). This change persisted through the end of the study at 24 months, at which time FDP foveal sensitivity was significantly decreased in the placebo group (-1.9 dB) and increased in the doxycycline group (+1.8 dB, p=0.02). However, changes among other functional and anatomic markers were insignificant. These data appear to suggest that there may be an inflammatory component in the pathogenesis of diabetic retinopathy that can be impaired with doxycycline.

More from this author: Argus II retinal prosthesis significantly improves spatial vision in blind patients, Artificial cornea is well retained in patients with ocular surface disease, High prevalence of undiagnosed glaucoma in West Africa, Interferon therapy is superior to methotrexate for uveitis, Rho kinase inhibitor safely reduces intraocular pressure

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: diabetic retinopathydoxycyclinefoveal sensitivityfrequency doubling perimetryOphthalmologyplacebotreatment groupvision
Previous Post

Gender differences in mental health after moving from poverty

Next Post

Rigorousness of Phase III trials for lung cancer may be declining

RelatedReports

Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab noninferior to aflibercept for treatment of neovascular age-related macular degeneration

March 9, 2022
Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab may improve visual acuity in patients with diabetic macular edema

March 8, 2022
Majority of pediatric medication-related visits to emergency department are preventable
Gastroenterology

Open-label placebo effective therapy for children with functional abdominal pain or irritable bowel syndrome

February 7, 2022
Adalimumab aids in control of noninfectious uveitis
Chronic Disease

Low-energy femtosecond laser-assisted cataract surgery versus conventional phacoemulsification

December 20, 2021
Next Post
Afatinib shows increased progression-free survival in non-small-cell lung cancer

Rigorousness of Phase III trials for lung cancer may be declining

Palliative chemotherapy associated with more ICU treatment at end-of-life

Palliative chemotherapy associated with more ICU treatment at end-of-life

Classics Series, Landmark Trials in Medicine

Magnesium sulfate in torsade de pointes [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.